ANIP - ANI Pharmaceuticals, Inc.
56.56 0.00 (0.00%)
After hours: 4:00PM EST
| Previous Close | 56.08 |
| Open | 56.06 |
| Bid | 56.00 x 800 |
| Ask | 58.95 x 800 |
| Day's Range | 55.95 - 57.49 |
| 52 Week Range | 36.92 - 86.96 |
| Volume | 75,239 |
| Avg. Volume | 192,930 |
| Market Cap | 683.867M |
| Beta (3Y Monthly) | 2.20 |
| PE Ratio (TTM) | 42.30 |
| EPS (TTM) | 1.34 |
| Earnings Date | Nov 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 75.00 |
- Simply Wall St.
Estimating The Intrinsic Value Of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of ANI Pharmaceuticals...
- Zacks
ANI Pharmaceuticals (ANIP) Lags Q3 Earnings and Revenue Estimates
ANI (ANIP) delivered earnings and revenue surprises of -16.89% and -10.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
ANI Pharmaceuticals Reports Third Quarter Results
BAUDETTE, Minn. , Nov. 6, 2019 /PRNewswire/ -- For the third quarter 2019: Net revenues of $51.3 million , an increase of 1% versus prior year GAAP net income of $3.9 million and diluted GAAP earnings ...
- Benzinga
The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 5.) Agile Therapeutics Inc (NASDAQ: AGRX ) (follow-on ...
- PR Newswire
ANI Announces Plans to Launch Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml) for Ventricular Arrhythmias
BAUDETTE, Minn., Oct. 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced that its partner Pharmaceutics International Inc. (Pii) has received FDA approval of a Prior Approval Supplement for Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml). ANI plans to launch this currently unavailable drug in December, introducing this critical drug for the treatment of ventricular fibrillation and life-threatening ventricular arrhythmias, such as ventricular tachycardia.
- PR Newswire
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2019 Financial Results
BAUDETTE, Minn. , Oct. 30, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2019 financial results on Wednesday, ...
- Zacks
ANI Pharmaceuticals (ANIP) to Report Q3 Results: Wall Street Expects Earnings Growth
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
ANI Pharmaceuticals announces the launch of ANI Global Source, its contract development and manufacturing business
BAUDETTE, Minn. , Oct. 29, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP), an experienced specialty pharmaceutical and contract development & manufacturing organization ...
- Insider Monkey
Here is What Hedge Funds Think About ANI Pharmaceuticals Inc (ANIP)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 730 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of June […]
- Simply Wall St.
Does ANI Pharmaceuticals (NASDAQ:ANIP) Deserve A Spot On Your Watchlist?
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
- Zacks
Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista
Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista
- Zacks
5 Stocks to Consider as New Analysts Initiate Coverage
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
- PR Newswire
ANI Announces Positive Clinical Results from Cortrophin® Gel Cortisol Response Study
The results indicate that ANI's Cortrophin® Gel (80 units/mL) is effective for its intended use. In addition, the clinical data demonstrate that ANI's modernized Cortrophin® Gel (80 units/mL) drug product has a cortisol response profile consistent with that observed in historical scientific literature that evaluated Cortrophin® Gel (44 units/mL) drug product manufactured in the 1960s (Brombacher et. al, 1969).
- PR Newswire
ANI Pharmaceuticals Announces Launch of Aspirin and Extended Release Dipyridamole Capsules, 25mg/200mg
BAUDETTE, Minn., Oct. 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Aspirin and Extended Release Dipyridamole Capsules, 25mg/200mg (the generic equivalent of Aggrenox®). This launch represents ANI's fifth generic product introduction in 2019. ANI acquired the rights to launch this drug in an acquisition executed in 2018. As part of that acquisition, ANI entered into a supply agreement for Aspirin and Extended Release Dipyridamole Capsules whereby ANI receives drug product, packaged in the ANI label, starting on October 1, 2019 and ending no later than March 1, 2021. ANI estimates that the current annual U.S. market for Aspirin and Extended Release Dipyridamole Capsules is approximately $80 million, based on Iqvia data. There are currently six suppliers of this drug in the U.S. market.
- Insider Monkey
Hedge Fund Mangrove Partners’ Top Stock Picks
Mangrove Partners was founded by Nathaniel August, who is also the fund’s president and portfolio manager. Mr August holds a B.A. from Brown University, and prior to launching his fund, he worked as a director at White Eagle Partners, as an Investment Analyst at K Capital Partners, as a Senior Analyst at Brahman Capital Partners, […]
- Simply Wall St.
ANI Pharmaceuticals (NASDAQ:ANIP) Takes On Some Risk With Its Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- PR Newswire
ANI Pharmaceuticals Announces Launch of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL
BAUDETTE, Minn., Sept. 11, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Vancomycin HCl for Oral Solution, 250mg per 5mL (the generic equivalent to ANI's Vancocin® for Oral Solution). To facilitate ease of administration the drug now includes a mixed berry taste, can be administered via nasogastric tube and does not contain any ingredients made with gluten-containing grain (wheat, barley, rye). The dye-free product is delivered in a single bottle format requiring simple reconstitution and offers dosing flexibility achieved through the availability of three different size bottles: 80mL, 150mL and 300mL. ANI estimates that the current annual U.S. vancomycin market is approximately $450 million. Arthur S. Przybyl, ANI's President and CEO stated, "This launch represents yet another successful re-commercialization for ANI of a previously discontinued drug and is our fourth generic product introduction in 2019. Our launch of Vancomycin for Oral Solution addresses an unmet need in the treatment of staph and C-diff infections and provides patients, physicians and pharmacists with a convenient, FDA-approved oral solution of vancomycin in addition to the currently available capsule and injectable forms. We are supporting this launch with an awareness campaign that leverages the existing virtual marketing infrastructure that we use to support our brand portfolio.
- Thomson Reuters StreetEvents
Edited Transcript of ANIP earnings conference call or presentation 7-Aug-19 2:30pm GMT
Q2 2019 ANI Pharmaceuticals Inc Earnings Call
- Simply Wall St.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Delivered A Weaker ROE Than Its Industry
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Motley FoolANI Pharmaceuticals Inc (ANIP) Q2 2019 Earnings Call Transcript
ANIP earnings call for the period ending June 30, 2019.
- Zacks
ANI Pharmaceuticals (ANIP) Q2 Earnings Surpass Estimates
ANI (ANIP) delivered earnings and revenue surprises of 11.63% and -2.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
ANI Pharmaceuticals Reports Second Quarter Results
BAUDETTE, Minn. , Aug. 7, 2019 /PRNewswire/ -- For the second quarter 2019: Net revenues of $54.4 million , an increase of 15% versus prior year GAAP net income of $6.6 million and diluted GAAP earnings ...
- PR Newswire
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2019 Financial Results
BAUDETTE, Minn. , July 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2019 financial results on ...
- Zacks
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
How Much is ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Getting Paid?
In 2013 Arthur Przybyl was appointed CEO of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). This report will, first, examine...
